Evidence map›Paper›PMID 30998425›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2019

Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Thomas R O'Brien, Howard A Young, Raymond P Donnelly, Ludmila Prokunina-Olsson

Abstract read
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The Interferon-Lambda Family Celebrates 20 Years of Scientific Discovery.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023
    Article
  2. Inhibition of SARS-CoV-2 by type I and type III interferons.The Journal of biological chemistry · 2020
    Article
  3. Interferon Lambda: An Immune System Factor That Cancer Epidemiologists Should Consider.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas R O'BrienInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Howard A YoungCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, Maryland.
Raymond P DonnellyDivision of Biotechnology Research and Review II, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Funding

Control of Cytokine Gene Expression in LymphoidMyeloid CellsZIABC009283 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YOUNG, HOWARD · 2009 to 2024
$22.7M
Epidemiology of Oncogenic VirusesZIACP005782 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI O'BRIEN, THOMAS R · 2009 to 2025
$6.7M
6 · The paper itself

Abstract

A meeting entitled, "Interferon Lambda: Disease Impact and Translational Potential," was held on the campus of the National Institutes of Health in Bethesda, Maryland, on October 25-26, 2018. To our knowledge, this was the first meeting that focused exclusively on interferon lambda (IFN-λ). The meeting's purpose was to enhance interdisciplinary communication and promote new collaborations. The gathering brought together an international group of scientists from a wide range of disciplines. Sessions included: IFN-λ Biology, Therapy and Genetic Variation; IFN-λ and Hepatitis C Virus Infection; IFN-λ in Other Infections; and IFN-λ-Hepatic Fibrosis and Cancer. The next meeting on IFN-λ is planned for 2020.

Indexed as

Hepatitis CInterferonsLiver CirrhosisCongresses as TopicHepacivirusHumansInterferon LambdaMarylandNational Institutes of Health (U.S.)United StatesInterferon LambdaInterferonscancergeneticshepatitis C virusimmunologyinfectious diseasesinterferon lambda

Identifiers

PMID30998425
PMCPMC6767859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.